Ser768
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser768  -  EGFR (human)

Site Information
DEAyVMAsVDNPHVC   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 452119

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 , 2 , 3 , 5 ) , western blotting ( 1 )
Disease tissue studied:
non-small cell lung cancer ( 2 , 3 )
Relevant cell line - cell type - tissue:
CHO (fibroblast) ( 1 ) , COS7 (fibroblast) ( 1 ) , Kyse450 (squamous) ( 5 ) , lymph node ( 2 )

Upstream Regulation
Kinases, in vitro:
CAMK2A (rat) ( 6 )
Treatments:
gefitinib ( 3 )

Downstream Regulation
Effects of modification on EGFR:
enzymatic activity, inhibited ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
esophageal cancer ( 5 ) , non-small cell lung cancer ( 2 , 3 , 4 )

References 

1

Huang LC, et al. (2018) Integrative annotation and knowledge discovery of kinase post-translational modifications and cancer-associated mutations through federated protein ontologies and resources. Sci Rep 8, 6518
29695735   Curated Info

2

Improta G, et al. (2016) Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. Oncol Lett 11, 393-398
26870223   Curated Info

3

Masago K, et al. (2010) Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol 40, 1105-9
20522446   Curated Info

4

Fu YN, et al. (2008) EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. Oncogene 27, 957-65
17653080   Curated Info

5

Guo M, et al. (2006) Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biol Ther 5, 152-5
16357520   Curated Info

6

Feinmesser RL, Wicks SJ, Taverner CJ, Chantry A (1999) Ca2+/calmodulin-dependent kinase II phosphorylates the epidermal growth factor receptor on multiple sites in the cytoplasmic tail and serine 744 within the kinase domain to regulate signal generation. J Biol Chem 274, 16168-73
10347170   Curated Info